Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Nippon Shinyaku: Sales, Profitability Show Signs of Recovery
November 25, 2002
-
ARCHIVE EAD Director Urges Wholesalers to Eliminate Inappropriate Trade Practices: FJPWA Seminar
November 25, 2002
-
ARCHIVE Ono: Mainstays Contribute to Sales, Profits Growth
November 25, 2002
-
ARCHIVE NEW PRODUCTS
November 25, 2002
-
ARCHIVE Dainippon: Sales Up, Profits Remain at Low Levels
November 25, 2002
-
ARCHIVE WEBSITE NEWS
November 25, 2002
-
ARCHIVE Tanabe Seiyaku: Record Profits Despite Lower Sales
November 25, 2002
-
ARCHIVE Pramipexole Reported as 1st-Line Treatment for Parkinson's Disease
November 18, 2002
-
ARCHIVE Azwell Taking Tougher Stance in Price Negotiations
November 18, 2002
-
ARCHIVE Boehringer Ingelheim, ImmunoGen Start Trial on New Anticancer Agent
November 18, 2002
-
ARCHIVE JPMA Exchanges Opinions with ABPI, SNIP
November 18, 2002
-
ARCHIVE Zyvox Effective against Diabetic Foot Infections: Pharmacia
November 18, 2002
-
ARCHIVE New Chugai Is Enjoying Synergism: President Nagayama
November 18, 2002
-
ARCHIVE Over 100 Mil. Prescriptions Issued for Pharmacia's Xalatan
November 18, 2002
-
ARCHIVE Consumers Want More Info from Drug Makers: JPMA Survey
November 18, 2002
-
ARCHIVE GSK Reports Results of Major Survey on COPD
November 18, 2002
-
ARCHIVE MPC: Merger Synergism Boosts Sales, Profits
November 18, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
November 18, 2002
-
ARCHIVE Arrow Japan to Diversify Business from Critical Care Products
November 18, 2002
-
ARCHIVE Terumo: Sales Up 3.4% in Japan, 8.1% Overseas
November 18, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…